If you are wondering whether AbbVie at around US$205 per share looks like good value or not, it helps to start by lining up ...

Is ABBV a good stock to buy? We came across a bullish thesis on AbbVie Inc. on X.com by @MoneyShow. In this article, we will ...

AbbVie has strong financials, a great dividend, and its stock trades at a modest valuation.

AbbVie stock (NYSE: ABBV) experienced a 5% decline yesterday, and the reason is evident: the U.S. FDA has just approved ...

With its focus on dividend aristocrat stocks, VIG has a strong track record for steady growth and dividend yields.

AbbVie (NYSE: ABBV), a pharmaceutical leader, has faced some challenges over the past three years. The company is managing some patent cliffs and clinical setbacks that worried investors and dinged ...

A decade ago, more than 63% of the pharmaceutical giant's revenue was tied up in one drug -- Humira. Granted, it was the ...

On December 10, HSBC increased its price target on AbbVie Inc. (NYSE:ABBV) from $225 to $265 and also upgraded the stock to Buy. Previously, on November 5, Piper Sandler reiterated a Buy rating on ...

AbbVie ABBV is set to report fourth-quarter and full-year 2025 earnings on Feb. 4, before the opening bell. The Zacks Consensus Estimate for the quarter’s sales and earnings is pegged at $16.36 ...

Some valuation metrics suggest that AbbVie is a cheap stock. The company's growth prospects through 2030 look attractive. AbbVie is also an excellent dividend stock. 10 stocks we like better than ...